ClinicalTrials.gg
TerminatedNCT03555149Updated Nov 7, 2023Results posted

A Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Colorectal Cancer (Morpheus-CRC)

A Phase 1/2 interventional study of Regorafenib and Atezolizumab in Colorectal Cancer, sponsored by Hoffmann-La Roche. Terminated at 15 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-11-07.

Sponsored by Hoffmann-La Roche · Phase 1/2, Interventional, and Treatment

Why this study was terminated
The Sponsor made the decision to terminate the study due to start up and recruitment issues caused by limited resource availability at the treating centers.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
96
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 59 studies testing regorafenib in Colorectal Neoplasms — 10 open to participants now, 15 under way, 3 of them phase 3. regorafenib · Colorectal Neoplasms.

Enrollment
22nd of 58
96 · median 55
Started
2018
with 3 others
Phase 1/2
8 of 59
2 open now
Registered
31st of 59
by date

Among the 59 studies testing regorafenib in Colorectal Neoplasms, this one is the 22nd largest by enrollment of the 58 interventional ones that give a count, is one of 4 that started in 2018, is one of 8 in phase 1/2, and was the 31st registered.

Colorectal Neoplasms

6,548 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

10 of the 59 studies testing regorafenib in Colorectal Neoplasms are open now, in 4 countries. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 10 open studies →

About regorafenib

regorafenib: first FDA approval 2012 (STIVARGA), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,179 Colorectal Neoplasms studies recruiting now, 762 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 59 studies testing regorafenib in Colorectal Neoplasms, or all of them as a file.
02

Study summary

A phase Ib/II, open-label, multicenter, randomized study designed to assess the safety, tolerability, pharmacokinetics and preliminary anti-tumor activity of immunotherapy-based treatment combinations in patients with metastatic colorectal cancer (mCRC) that became refractory to first- and second-line standard therapies. Eligible patients will be assigned to one of several treatment arms.

03

Conditions studied

  • Colorectal Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (ECOG) Performance Status of 0 or 1
  • ≥ 3 months, as determined by the investigator
  • confirmed adenocarcinoma originating from the colon or rectum
  • disease not amenable to local treatment
  • Disease progression during or following not more than two separate for metastatic colorectal cancer (mCRC) that consisted of fluoropyrimidine-, oxaliplatin-, and irinotecan-containing chemotherapy in combination with a biologic agent
  • (at least one target lesion) according to v1.1
  • Adequate hematologic and end-organ function obtained within 14 days prior to initiation of study treatment

Exclusion criteria

Exclusion Criteria:

  • High microsatellite instability (MSI-H) tumor
  • Presence of BRAFV600E mutation
  • Prior treatment with any of the protocol-specified study treatments
  • Prior treatment with T-cell co-stimulating or immune checkpoint blockade therapies including , anti-PD-1, and anti-PD-L1 therapeutic antibodies
  • Biologic treatment within 2 weeks prior to initiation of study treatment, or other systemic treatment for CRC within 2 weeks or 5 half-lives of the drug (whichever is shorter) prior to initiation of study treatment
  • Treatment with therapy within 28 days prior to initiation of study treatment
  • Eligibility only for the control arm
  • Prior allogeneic stem cell or solid organ transplantation
  • Treatment with systemic immunostimulatory agents within 4 weeks or 5 half-lives of the drug (whichever is longer) prior to the initiation of study treatment
  • Treatment with systemic medication within 2 weeks prior to initiation of study treatment, or anticipation of need for systemic immunosuppressant medication during study treatment
  • Treatment with a live, attenuated vaccine within 4 weeks prior to initiation of study treatment, or anticipation of need for such a vaccine during atezolizumab treatment or within 5 months after the last dose of atezolizumab
  • Current treatment with anti-viral therapy for
  • Uncontrolled pleural effusion, pericardial effusion, ascites requiring recurrent drainage procedures (once monthly or more frequently), or tumor related-pain,
  • Uncontrolled or symptomatic hypercalcemia (ionized calcium >1.5 mmol/L, calcium >12 mg/dL, or corrected serum calcium >)
  • Symptomatic, untreated, or actively progressing
  • History of
  • Active or history of disease or immune deficiency
  • History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening chest computed tomography (CT) scan
  • History of other than CRC within 2 years prior to screening, with the exception of malignancies with a negligible risk of or death
  • Active tuberculosis
  • Severe infection within 4 weeks prior to initiation of study treatment
  • Significant cardiovascular disease
  • Grade ≥3 hemorrhage or bleeding event within 28 days prior to initiation of study treatment
  • Major surgical procedure, other than for diagnosis, within 4 weeks prior to initiation of study treatment, or anticipation of need for a major surgical procedure during the study
  • History of severe allergic reactions to chimeric or humanized antibodies or fusion proteins
  • Inability to swallow medications
  • Malabsorption condition that would alter the absorption of orally administered medications
  • Evidence of inherited bleeding diathesis or significant coagulopathy at risk of bleeding
  • Urine dipstick ≥ 2+ protein or ≥ 3.5 g of protein in a 24-hour urine collection
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
96 participants (actual)

Study arms

  • Active comparator
    Regorafenib (Control)

    Participants will receive treatment until unacceptable toxicity or disease progression per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1.

    Drug: Regorafenib

  • Experimental
    Atezolizumab + Imprime PGG + Bevacizumab

    Participants will receive treatment until unacceptable toxicity or loss of clinical benefit as confirmed by disease progression per RECIST V1.1 or lack of continued benefit as determined by the investigator.

    Drug: Atezolizumab · Drug: Imprime PGG · Drug: Bevacizumab

  • Experimental
    Atezolizumab + Isatuximab

    Participants will receive treatment until unacceptable toxicity or loss of clinical benefit as confirmed by disease progression per RECIST V1.1 or lack of continued benefit as determined by the investigator.

    Drug: Atezolizumab · Drug: Isatuximab

  • Experimental
    Atezolizumab + Selicrelumab + Bevacizumab

    Participants will receive treatment until unacceptable toxicity or loss of clinical benefit as confirmed by disease progression per RECIST V1.1 or lack of continued benefit as determined by the investigator.

    Drug: Atezolizumab · Drug: Bevacizumab · Drug: Selicrelumab

  • Experimental
    Atezolizumab + Idasanutlin

    Participants will receive treatment until unacceptable toxicity or loss of clinical benefit as confirmed by disease progression per RECIST V1.1 or lack of continued benefit as determined by the investigator.

    Drug: Atezolizumab · Drug: Idasanutlin

  • Experimental
    Atezolizumab + Regorafenib

    Participants will receive treatment until unacceptable toxicity or loss of clinical benefit as confirmed by disease progression per RECIST V1.1 or lack of continued benefit as determined by the investigator.

    Drug: Regorafenib · Drug: Atezolizumab

  • Experimental
    Atezolizumab + Regorafenib + AB928

    Participants will receive treatment until unacceptable toxicity or loss of clinical benefit as confirmed by disease progression per RECIST V1.1 or lack of continued benefit as determined by the investigator.

    Drug: Regorafenib · Drug: Atezolizumab · Drug: AB928

  • Experimental
    Atezolizumab + LOAd703

    Participants will receive treatment until unacceptable toxicity or loss of clinical benefit as confirmed by disease progression per RECIST V1.1 or lack of continued benefit as determined by the investigator.

    Drug: Atezolizumab · Genetic: LOAd703

Interventions

  • Regorafenib will be administered orally on Days 1-21 of each 28-day cycle.

  • Atezolizumab will be administered by intravenous (IV) infusion every 3 weeks (Q3W) on Day 1 of 21-day cycles, with the exception of the Atezolizumab + Selicrelumab + Bevacizumab, Atezolizumab + Idasanutlin, Atezolizumab + Regorafenib and Atezolizumab + Regorafenib + AB928 arms where the Atezolizumab will be administered by IV infusion every 2 weeks (Q2W) on Days 1 and 15 of each 28-day cycle.

  • Imprime PGG will be administered by IV infusion weekly on Days 1, 8, and 15 of each 21-day cycle.

  • Bevacizumab will be administered by IV infusion on Day 1 of each 21-day cycle for the Atezolizumab + Imprime PGG + Bevacizumab arm, and on Day 1 and Day 15 of each 28-day cycle for the Atezolizumab + Selicrelumab + Bevacizumab arm.

  • Isatuximab will be administered on Day 1, 8 and 15 of cycle 1 and on day 1 of all subsequent cycles. Cycles will be 21 days long.

  • Selicrelumab will be administered by subcutaneous (SC) injection on Day 1 of cycles 1-4 and every third cycle thereafter. Cycles will be 28 days long.

  • Idasanutlin will be administered orally on Days 1-5 of each 28-day cycle.

  • DrugAB928

    AB928 will be administered orally once daily on Days 1-28 of each 28-day cycle.

  • GeneticLOAd703

    LOAd703 will be administered by intratumoral injection on Day 1 of each 21-day cycle.

    Also known as: Delolimogene mupadenorepvec

06

What researchers measure

Primary outcomes

  1. Best Confirmed Overall Response Rate (ORR) as Determined by the Investigator According to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1

    The best confirmed overall response rate (ORR) is defined as the percentage of participants with a complete response or partial response on two consecutive occasions ≥4 weeks apart, as determined by the investigator according to RECIST v1.1. Participants could be classified as "Stable Disease" if the assessment was at least 6 weeks from randomization. Participants were classified as Missing if no post-baseline response assessments were available. Participants were classified as Not Evaluable if all post-baseline response assessments were unevaluable. The differences in ORR between the experimental arms and the corresponding control arm were calculated, along with 95% confidence intervals (CIs), using normal approximation of the binomial distribution. The 95% CIs for ORRs were constructed using the Clopper-Pearson method. The 95% CIs for the difference in rates were constructed using the Wald method with continuity correction.

    Time frame: From randomization until disease progression or loss of clinical benefit (up to 4 years)

Secondary outcomes

  1. Progression-Free Survival (PFS) as Determined by Investigator According to RECIST v1.1

    Progression-free survival (PFS) after randomization, defined as the time from randomization to the first occurrence of disease progression or death from any cause (whichever occurs first), was determined by the investigator according to RECIST v1.1. For participants who did not have documented disease progression or death, PFS was censored at the day of the last tumor assessment. The Kaplan-Meier method was used to estimate the median for PFS with 95% confidence intervals (CIs) constructed through use of the Brookmeyer and Crowley method.

    Time frame: From randomization up to the first occurrence of disease or death from any cause (up to 4 years)

  2. Overall Survival (OS)

    Overall survival (OS) is defined as the time from randomization to death from any cause. Participants who were still alive at the time of OS analysis were censored at the last date they were known to be alive. The Kaplan-Meier method was used to estimate the median for OS with 95% confidence intervals (CIs) constructed through use of the Brookmeyer and Crowley method.

    Time frame: From randomization up to death from any cause (up to 4 years)

  3. Percentage of Participants Who Were Alive at Landmark Timepoints for Overall Survival (OS)

    Overall survival (OS) is defined as the time from randomization to death from any cause. Participants who were still alive at the time of OS analysis were censored at the last date they were known to be alive. OS is shown as the percentage of participants who were event-free at the landmark timepoints of 3, 6, 12, and 18 months.

    Time frame: 3, 6, 12, and 18 months

  4. Duration of Response (DOR) as Determined by the Investigator According to RECIST v1.1

    Duration of response is defined as the time from the first occurrence of a documented objective response to disease progression or death from any cause.

    Time frame: From the date of first occurrence of a documented objective response to disease progression or death from any cause, whichever occurs first (up to 4 years)

  5. Disease Control Rate (DCR), as Determined by the Investigator Per RECIST v1.1

    Disease control rate is defined as the percentage of participants with stable disease for ≥12 weeks or a complete or partial response, as determined by the investigator according to RECIST v1.1.

    Time frame: From randomization until disease progression or loss of clinical benefit (up to 4 years)

  6. Percentage of Participants With at Least One Adverse Event (AE)

    The incidence, nature, and severity of adverse events (AEs) are reported, with severity determined according to NCI CTCAE v4.0. All AEs were reported until 30 days after the last study dose or until start of new systemic anti-cancer therapy. Serious AEs and AEs of special interest were reported until 135 days (or 180 days for the Atezolizumab + LOAd703 arm only) after the last dose of study treatment.

    Time frame: Adverse event data were collected from baseline up to 6 months after the last dose of study treatment (up to 640 days); deaths (all-cause) were reported from baseline through survival follow-up (up to 4 years)

07

Results

Posted Nov 7, 2023
Limitations and caveats
This study is not designed to make explicit power and Type I error considerations for a hypothesis test. Instead, this study is designed to obtain preliminary efficacy, safety, and PK data. No formal statistical hypothesis testing was performed in this study. Due to the limited sample size, the results need to be interpreted with caution. For the Atezo+Idasa and Atezo+LOAd703 groups, no meaningful conclusion could be drawn because these experimental arms have been terminated prematurely.

Participant flow

The study was conducted at 15 centers in 5 countries: United States, France, Republic of Korea, Australia, and Switzerland.

Participant flow — Overall Study
MilestoneRegorafenib (Control)Atezolizumab + Imprime PGG + BevacizumabAtezolizumab + IsatuximabAtezolizumab + Selicrelumab + BevacizumabAtezolizumab + IdasanutlinAtezolizumab + RegorafenibAtezolizumab + Regorafenib + AB928Atezolizumab + LOAd703
Started2415156415152
Received at least one dose of study treatment1915156415152
Completed00000000
Not completed2415156415152
Withdrew: Death1815154411121
Withdrew: Lost to follow-up10000100
Withdrew: Physician decision10000000
Withdrew: Study terminated by sponsor10000231
Withdrew: Withdrawal by subject30020100

Outcome measures

PrimaryBest Confirmed Overall Response Rate (ORR) as Determined by the Investigator According to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1

The best confirmed overall response rate (ORR) is defined as the percentage of participants with a complete response or partial response on two consecutive occasions ≥4 weeks apart, as determined by the investigator according to RECIST v1.1. Participants could be classified as "Stable Disease" if the assessment was at least 6 weeks from randomization. Participants were classified as Missing if no post-baseline response assessments were available. Participants were classified as Not Evaluable if all post-baseline response assessments were unevaluable. The differences in ORR between the experimental arms and the corresponding control arm were calculated, along with 95% confidence intervals (CIs), using normal approximation of the binomial distribution. The 95% CIs for ORRs were constructed using the Clopper-Pearson method. The 95% CIs for the difference in rates were constructed using the Wald method with continuity correction.

Time frame:
From randomization until disease progression or loss of clinical benefit (up to 4 years)
Reported as:
Number · Percentage of Participants
Best Confirmed Overall Response Rate (ORR) as Determined by the Investigator According to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1
Percentage of ParticipantsRegorafenib (Control)Atezolizumab + Imprime PGG + BevacizumabAtezolizumab + IsatuximabAtezolizumab + Selicrelumab + BevacizumabAtezolizumab + IdasanutlinAtezolizumab + RegorafenibAtezolizumab + Regorafenib + AB928Atezolizumab + LOAd703
Responders (CR + PR)0 (0 to 17.65)0 (0 to 21.80)0 (0 to 21.80)0 (0 to 45.93)0 (0 to 60.24)6.7 (0.17 to 31.95)6.7 (0.17 to 31.95)0 (0 to 84.19)
Complete Response (CR)0 (0 to 17.65)0 (0 to 21.80)0 (0 to 21.80)0 (0 to 45.93)0 (0 to 60.24)0 (0 to 21.80)0 (0 to 21.80)0 (0 to 84.19)
Partial Response (PR)0 (0 to 17.65)0 (0 to 21.80)0 (0 to 21.80)0 (0 to 45.93)0 (0 to 60.24)6.7 (0.17 to 31.95)6.7 (0.17 to 31.95)0 (0 to 84.19)
Stable Disease (SD)63.2 (38.36 to 83.71)33.3 (11.82 to 61.62)20.0 (4.33 to 48.09)50 (11.81 to 88.19)0 (0 to 60.24)33.3 (11.82 to 61.62)53.3 (26.59 to 78.73)0 (0 to 84.19)
Progressive Disease (PD)26.3 (9.15 to 51.20)66.7 (38.38 to 88.18)66.7 (38.38 to 88.18)33.3 (4.33 to 77.72)100 (39.76 to 100)46.7 (21.27 to 73.41)26.7 (7.79 to 55.10)100 (15.81 to 100)
Not Evaluable0 (NA to NA)0 (NA to NA)13.3 (NA to NA)0 (NA to NA)0 (NA to NA)0 (NA to NA)13.3 (NA to NA)0 (NA to NA)
Missing10.5 (NA to NA)0 (NA to NA)0 (NA to NA)16.7 (NA to NA)0 (NA to NA)13.3 (NA to NA)0 (NA to NA)0 (NA to NA)
Statistical analysis
  • Regorafenib (Control) vs Atezolizumab + Regorafenib · Difference in overall response rate: 6.67 · 95% CI -11.92 to 25.25The difference in ORR was calculated as the experimental arm (Atezolizumab + Regorafenib) subtracted from the control arm (Regorafenib).
  • Regorafenib (Control) vs Atezolizumab + Regorafenib + AB928 · Difference in overall response rate: 6.67 · 95% CI -11.92 to 25.25The difference in ORR was calculated as the experimental arm (Atezolizumab + Regorafenib + AB928) subtracted from the control arm (Regorafenib).
SecondaryProgression-Free Survival (PFS) as Determined by Investigator According to RECIST v1.1

Progression-free survival (PFS) after randomization, defined as the time from randomization to the first occurrence of disease progression or death from any cause (whichever occurs first), was determined by the investigator according to RECIST v1.1. For participants who did not have documented disease progression or death, PFS was censored at the day of the last tumor assessment. The Kaplan-Meier method was used to estimate the median for PFS with 95% confidence intervals (CIs) constructed through use of the Brookmeyer and Crowley method.

Time frame:
From randomization up to the first occurrence of disease or death from any cause (up to 4 years)
Reported as:
Median · Months
Progression-Free Survival (PFS) as Determined by Investigator According to RECIST v1.1
MonthsRegorafenib (Control)Atezolizumab + Imprime PGG + BevacizumabAtezolizumab + IsatuximabAtezolizumab + Selicrelumab + BevacizumabAtezolizumab + IdasanutlinAtezolizumab + RegorafenibAtezolizumab + Regorafenib + AB928Atezolizumab + LOAd703
Progression-Free Survival (PFS) as Determined by Investigator According to RECIST v1.12.83 (2.20 to 3.02)1.51 (1.38 to 2.79)1.41 (1.41 to 1.77)4.21 (1.68 to NA)1.26 (0.82 to NA)1.81 (1.38 to 2.96)4.60 (2.60 to 5.78)1.58 (1.51 to NA)
Statistical analysis
  • Regorafenib (Control) vs Atezolizumab + Imprime PGG + Bevacizumab · Hazard ratio (hr): 1.35 · 95% CI 0.67 to 2.73
  • Regorafenib (Control) vs Atezolizumab + Isatuximab · Hazard ratio (hr): 2.30 · 95% CI 1.08 to 4.88
  • Regorafenib (Control) vs Atezolizumab + Selicrelumab + Bevacizumab · Hazard ratio (hr): 0.79 · 95% CI 0.29 to 2.18
  • Regorafenib (Control) vs Atezolizumab + Idasanutlin · Hazard ratio (hr): 2.00 · 95% CI 0.64 to 6.24
  • Regorafenib (Control) vs Atezolizumab + Regorafenib · Hazard ratio (hr): 1.74 · 95% CI 0.83 to 3.63
  • Regorafenib (Control) vs Atezolizumab + Regorafenib + AB928 · Hazard ratio (hr): 0.80 · 95% CI 0.39 to 1.63
  • Regorafenib (Control) vs Atezolizumab + LOAd703 · Hazard ratio (hr): 5.64 · 95% CI 0.94 to 33.82
SecondaryOverall Survival (OS)

Overall survival (OS) is defined as the time from randomization to death from any cause. Participants who were still alive at the time of OS analysis were censored at the last date they were known to be alive. The Kaplan-Meier method was used to estimate the median for OS with 95% confidence intervals (CIs) constructed through use of the Brookmeyer and Crowley method.

Time frame:
From randomization up to death from any cause (up to 4 years)
Reported as:
Median · Months
Overall Survival (OS)
MonthsRegorafenib (Control)Atezolizumab + Imprime PGG + BevacizumabAtezolizumab + IsatuximabAtezolizumab + Selicrelumab + BevacizumabAtezolizumab + IdasanutlinAtezolizumab + RegorafenibAtezolizumab + Regorafenib + AB928Atezolizumab + LOAd703
Overall Survival (OS)10.15 (4.40 to 12.29)5.72 (4.37 to 10.51)5.13 (3.12 to 7.75)14.36 (3.22 to NA)5.93 (1.61 to NA)11.01 (5.29 to 16.66)8.67 (6.60 to 14.62)4.07 (NA to NA)
Statistical analysis
  • Regorafenib (Control) vs Atezolizumab + Imprime PGG + Bevacizumab · Hazard ratio (hr): 1.44 · 95% CI 0.71 to 2.93
  • Regorafenib (Control) vs Atezolizumab + Isatuximab · Hazard ratio (hr): 1.38 · 95% CI 0.68 to 2.81
  • Regorafenib (Control) vs Atezolizumab + Selicrelumab + Bevacizumab · Hazard ratio (hr): 0.90 · 95% CI 0.30 to 2.72
  • Regorafenib (Control) vs Atezolizumab + Idasanutlin · Hazard ratio (hr): 1.27 · 95% CI 0.42 to 3.84
  • Regorafenib (Control) vs Atezolizumab + Regorafenib · Hazard ratio (hr): 0.86 · 95% CI 0.39 to 1.88
  • Regorafenib (Control) vs Atezolizumab + Regorafenib + AB928 · Hazard ratio (hr): 0.92 · 95% CI 0.43 to 1.96
  • Regorafenib (Control) vs Atezolizumab + LOAd703 · Hazard ratio (hr): 2.88 · 95% CI 0.33 to 24.85
SecondaryPercentage of Participants Who Were Alive at Landmark Timepoints for Overall Survival (OS)

Overall survival (OS) is defined as the time from randomization to death from any cause. Participants who were still alive at the time of OS analysis were censored at the last date they were known to be alive. OS is shown as the percentage of participants who were event-free at the landmark timepoints of 3, 6, 12, and 18 months.

Time frame:
3, 6, 12, and 18 months
Reported as:
Number · Percentage of Participants
Percentage of Participants Who Were Alive at Landmark Timepoints for Overall Survival (OS)
Percentage of ParticipantsRegorafenib (Control)Atezolizumab + Imprime PGG + BevacizumabAtezolizumab + IsatuximabAtezolizumab + Selicrelumab + BevacizumabAtezolizumab + IdasanutlinAtezolizumab + RegorafenibAtezolizumab + Regorafenib + AB928Atezolizumab + LOAd703
3 Months84.21 (67.81 to 100)100.00 (100.00 to 100.00)73.33 (50.95 to 95.71)100.00 (100.00 to 100.00)75.00 (32.57 to 100.00)78.97 (57.78 to 100.00)86.67 (69.46 to 100.00)100.00 (100.00 to 100.00)
6 Months63.16 (41.47 to 84.85)46.67 (21.42 to 71.91)40.00 (15.21 to 64.79)80.00 (44.94 to 100.00)50.00 (1.00 to 99.00)71.79 (48.32 to 95.27)73.33 (50.95 to 95.71)—
12 Months34.45 (12.42 to 56.48)20.00 (0.00 to 40.24)26.67 (4.29 to 49.05)53.33 (4.68 to 100)25.00 (0.00 to 67.43)39.89 (13.18 to 66.59)33.33 (9.48 to 57.19)—
18 Months17.22 (0.00 to 34.87)6.67 (0.00 to 19.29)20.00 (0.00 to 40.24)26.67 (0.00 to 70.97)25.00 (0.00 to 67.43)23.93 (0.48 to 47.39)26.67 (4.29 to 49.05)—
Statistical analysis
  • Regorafenib (Control) vs Atezolizumab + Imprime PGG + Bevacizumab · Difference in os event-free rate: 15.79 · 95% CI -0.61 to 32.19
  • Regorafenib (Control) vs Atezolizumab + Imprime PGG + Bevacizumab · Difference in os event-free rate: -16.49 · 95% CI -49.78 to 16.79
  • Regorafenib (Control) vs Atezolizumab + Imprime PGG + Bevacizumab · Difference in os event-free rate: -14.45 · 95% CI -44.37 to 15.47
  • Regorafenib (Control) vs Atezolizumab + Imprime PGG + Bevacizumab · Difference in os event-free rate: -10.56 · 95% CI -32.25 to 11.14
  • Regorafenib (Control) vs Atezolizumab + Isatuximab · Difference in os event-free rate: -10.88 · 95% CI -38.62 to 16.87
  • Regorafenib (Control) vs Atezolizumab + Isatuximab · Difference in os event-free rate: -23.16 · 95% CI -56.10 to 9.78
  • Regorafenib (Control) vs Atezolizumab + Isatuximab · Difference in os event-free rate: -7.78 · 95% CI -39.19 to 23.62
  • Regorafenib (Control) vs Atezolizumab + Isatuximab · Difference in os event-free rate: 2.78 · 95% CI -24.08 to 29.63
  • Regorafenib (Control) vs Atezolizumab + Selicrelumab + Bevacizumab · Difference in os event-free rate: 15.79 · 95% CI -0.61 to 32.19
  • Regorafenib (Control) vs Atezolizumab + Selicrelumab + Bevacizumab · Difference in os event-free rate: 16.84 · 95% CI -24.39 to 58.07
  • Regorafenib (Control) vs Atezolizumab + Selicrelumab + Bevacizumab · Difference in os event-free rate: 18.88 · 95% CI -34.53 to 72.30
  • Regorafenib (Control) vs Atezolizumab + Selicrelumab + Bevacizumab · Difference in os event-free rate: 9.44 · 95% CI -38.19 to 57.08
  • Regorafenib (Control) vs Atezolizumab + Idasanutlin · Difference in os event-free rate: -9.21 · 95% CI -54.70 to 36.28
  • Regorafenib (Control) vs Atezolizumab + Idasanutlin · Difference in os event-free rate: -13.16 · 95% CI -66.74 to 40.43
  • Regorafenib (Control) vs Atezolizumab + Idasanutlin · Difference in os event-free rate: -9.45 · 95% CI -57.26 to 38.36
  • Regorafenib (Control) vs Atezolizumab + Idasanutlin · Difference in os event-free rate: 7.78 · 95% CI -38.18 to 53.73
  • Regorafenib (Control) vs Atezolizumab + Regorafenib · Difference in os event-free rate: -5.24 · 95% CI -32.03 to 21.56
  • Regorafenib (Control) vs Atezolizumab + Regorafenib · Difference in os event-free rate: 8.64 · 95% CI -23.33 to 40.60
  • Regorafenib (Control) vs Atezolizumab + Regorafenib · Difference in os event-free rate: 5.44 · 95% CI -29.19 to 40.06
  • Regorafenib (Control) vs Atezolizumab + Regorafenib · Difference in os event-free rate: 6.71 · 95% CI -22.64 to 36.06
  • Regorafenib (Control) vs Atezolizumab + Regorafenib + AB928 · Difference in os event-free rate: 2.46 · 95% CI -21.31 to 26.22
  • Regorafenib (Control) vs Atezolizumab + Regorafenib + AB928 · Difference in os event-free rate: 10.18 · 95% CI -20.99 to 41.34
  • Regorafenib (Control) vs Atezolizumab + Regorafenib + AB928 · Difference in os event-free rate: -1.12 · 95% CI -33.59 to 31.36
  • Regorafenib (Control) vs Atezolizumab + Regorafenib + AB928 · Difference in os event-free rate: 9.44 · 95% CI -19.06 to 37.94
  • Regorafenib (Control) vs Atezolizumab + LOAd703 · Difference in os event-free rate: 15.79 · 95% CI -0.61 to 32.19
SecondaryDuration of Response (DOR) as Determined by the Investigator According to RECIST v1.1

Duration of response is defined as the time from the first occurrence of a documented objective response to disease progression or death from any cause.

Time frame:
From the date of first occurrence of a documented objective response to disease progression or death from any cause, whichever occurs first (up to 4 years)
Reported as:
Median · Months
Duration of Response (DOR) as Determined by the Investigator According to RECIST v1.1
MonthsRegorafenib (Control)Atezolizumab + Imprime PGG + BevacizumabAtezolizumab + IsatuximabAtezolizumab + Selicrelumab + BevacizumabAtezolizumab + IdasanutlinAtezolizumab + RegorafenibAtezolizumab + Regorafenib + AB928Atezolizumab + LOAd703
Duration of Response (DOR) as Determined by the Investigator According to RECIST v1.1—————3.12 (NA to NA)5.75 (NA to NA)—
SecondaryDisease Control Rate (DCR), as Determined by the Investigator Per RECIST v1.1

Disease control rate is defined as the percentage of participants with stable disease for ≥12 weeks or a complete or partial response, as determined by the investigator according to RECIST v1.1.

Time frame:
From randomization until disease progression or loss of clinical benefit (up to 4 years)
Reported as:
Number · Percentage of Participants
Disease Control Rate (DCR), as Determined by the Investigator Per RECIST v1.1
Percentage of ParticipantsRegorafenib (Control)Atezolizumab + Imprime PGG + BevacizumabAtezolizumab + IsatuximabAtezolizumab + Selicrelumab + BevacizumabAtezolizumab + IdasanutlinAtezolizumab + RegorafenibAtezolizumab + Regorafenib + AB928Atezolizumab + LOAd703
Disease Control Rate (DCR), as Determined by the Investigator Per RECIST v1.115.8 (3.38 to 39.58)13.3 (1.66 to 40.46)6.7 (0.17 to 31.95)33.3 (4.33 to 77.72)0 (0.00 to 60.24)13.3 (1.66 to 40.46)40.0 (16.34 to 67.71)0 (0.00 to 84.19)
SecondaryPercentage of Participants With at Least One Adverse Event (AE)

The incidence, nature, and severity of adverse events (AEs) are reported, with severity determined according to NCI CTCAE v4.0. All AEs were reported until 30 days after the last study dose or until start of new systemic anti-cancer therapy. Serious AEs and AEs of special interest were reported until 135 days (or 180 days for the Atezolizumab + LOAd703 arm only) after the last dose of study treatment.

Time frame:
Adverse event data were collected from baseline up to 6 months after the last dose of study treatment (up to 640 days); deaths (all-cause) were reported from baseline through survival follow-up (up to 4 years)
Reported as:
Number · Percentage of Participants
Percentage of Participants With at Least One Adverse Event (AE)
Percentage of ParticipantsRegorafenib (Control)Atezolizumab + Imprime PGG + BevacizumabAtezolizumab + IsatuximabAtezolizumab + Selicrelumab + BevacizumabAtezolizumab + IdasanutlinAtezolizumab + RegorafenibAtezolizumab + Regorafenib + AB928Atezolizumab + LOAd703
Adverse Event (AE)100100100100100100100100
Death89.510010066.710073.380.050.0
Withdrawn from Stage due to an AE15.86.70006.76.70
AE with a Fatal Outcome10.500006.700
Serious AE (SAE)26.36.733.350.025.046.746.750.0
SAE Leading to Withdrawal from any Treatment21.16.70006.700
SAE Leading to Dose Modification/Interruption5.306.750.0026.746.70
Related SAE5.36.7050.025.026.733.350.0
AE Leading to Withdrawal from any Treatment26.36.700020.06.70
AE Leading to Dose Modification/Interruption63.240.013.350.075.086.793.30
Related AE94.786.786.710010093.310050.0
Related AE Leading to Withdrawal from any Treatment10.56.70006.76.70
Related AE Leading to Dose Modification/Interruption47.433.3033.375.073.393.30
Grade 3-5 AE68.420.046.750.075.066.760.00
Worst Grade AE: 510.500006.700
Worst Grade AE: 45.306.7025.06.713.30
Worst Grade AE: 352.620.040.050.050.053.346.70

Adverse events

Collected over Adverse event data were collected from first study dose up to 6 months after the last dose of study treatment (up to 640 days); deaths (all-cause) were reported from enrolment through survival follow-up (up to 4 years).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Regorafenib (Control)18/24 (75%)5/19 (26.3%)19/19 (100%)
Atezolizumab + Imprime PGG + Bevacizumab15/15 (100%)1/15 (6.7%)15/15 (100%)
Atezolizumab + Isatuximab15/15 (100%)5/15 (33.3%)15/15 (100%)
Atezolizumab + Selicrelumab + Bevacizumab4/6 (66.7%)3/6 (50%)6/6 (100%)
Atezolizumab + Idasanutlin4/4 (100%)1/4 (25%)4/4 (100%)
Atezolizumab + Regorafenib11/15 (73.3%)7/15 (46.7%)15/15 (100%)
Atezolizumab + Regorafenib + AB92812/15 (80%)7/15 (46.7%)15/15 (100%)
Atezolizumab + LOAd7031/2 (50%)1/2 (50%)2/2 (100%)
Most frequent serious events
Showing 10 of 38
Most frequent serious events
EventRegorafenib (Control)Atezolizumab + Imprime PGG + BevacizumabAtezolizumab + IsatuximabAtezolizumab + Selicrelumab + BevacizumabAtezolizumab + IdasanutlinAtezolizumab + RegorafenibAtezolizumab + Regorafenib + AB928Atezolizumab + LOAd703
Cytokine release syndromeImmune system disorders0/190/150/150/60/40/150/151/2
ThrombocytopeniaBlood and lymphatic system disorders0/190/150/150/61/40/150/150/2
PyrexiaGeneral disorders0/190/150/150/60/43/152/150/2
Atrial flutterCardiac disorders0/190/150/151/60/40/150/150/2
DiarrhoeaGastrointestinal disorders0/190/150/151/60/40/150/150/2
Small intestinal obstructionGastrointestinal disorders0/190/151/151/60/40/150/150/2
VomitingGastrointestinal disorders1/190/150/151/60/40/150/150/2
SyncopeNervous system disorders0/190/150/151/60/40/150/150/2
EpistaxisRespiratory, thoracic and mediastinal disorders0/190/150/151/60/40/150/150/2
HaemoptysisRespiratory, thoracic and mediastinal disorders0/190/151/151/60/40/150/150/2
Most frequent other events
Showing 10 of 198
Most frequent other events
EventRegorafenib (Control)Atezolizumab + Imprime PGG + BevacizumabAtezolizumab + IsatuximabAtezolizumab + Selicrelumab + BevacizumabAtezolizumab + IdasanutlinAtezolizumab + RegorafenibAtezolizumab + Regorafenib + AB928Atezolizumab + LOAd703
NauseaGastrointestinal disorders7/193/156/150/64/43/152/151/2
VomitingGastrointestinal disorders1/194/153/151/64/43/152/150/2
FatigueGeneral disorders8/197/159/152/61/47/154/152/2
Injection site reactionGeneral disorders0/190/150/155/60/40/150/150/2
Infusion related reactionInjury, poisoning and procedural complications0/198/1511/150/60/42/154/150/2
Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders12/190/150/150/60/45/154/150/2
Abdominal distensionGastrointestinal disorders0/190/151/150/61/41/150/151/2
Abdominal painGastrointestinal disorders5/193/154/150/61/41/154/151/2
DiarrhoeaGastrointestinal disorders6/196/152/152/62/47/154/150/2
Cytokine release syndromeImmune system disorders0/190/150/150/60/40/150/151/2

Baseline characteristics

All participants who were randomized in the study, regardless of whether they actually received any study treatment.

Age, Continuous
Age, Continuous(Years)Regorafenib (Control)Atezolizumab + Imprime PGG + BevacizumabAtezolizumab + IsatuximabAtezolizumab + Selicrelumab + BevacizumabAtezolizumab + IdasanutlinAtezolizumab + RegorafenibAtezolizumab + Regorafenib + AB928Atezolizumab + LOAd703Total
Age (year)59.5 ± 10.357.8 ± 5.952.3 ± 12.066.8 ± 10.056.3 ± 6.856.4 ± 8.255.1 ± 9.258.0 ± 11.357.2 ± 9.7
Sex: Female, Male
Sex: Female, Male(Participants)Regorafenib (Control)Atezolizumab + Imprime PGG + BevacizumabAtezolizumab + IsatuximabAtezolizumab + Selicrelumab + BevacizumabAtezolizumab + IdasanutlinAtezolizumab + RegorafenibAtezolizumab + Regorafenib + AB928Atezolizumab + LOAd703Total
Female127613114145
Male128951411151
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Regorafenib (Control)Atezolizumab + Imprime PGG + BevacizumabAtezolizumab + IsatuximabAtezolizumab + Selicrelumab + BevacizumabAtezolizumab + IdasanutlinAtezolizumab + RegorafenibAtezolizumab + Regorafenib + AB928Atezolizumab + LOAd703Total
Hispanic or Latino2431010112
Not Hispanic or Latino211011441114176
Unknown or Not Reported111103108
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Regorafenib (Control)Atezolizumab + Imprime PGG + BevacizumabAtezolizumab + IsatuximabAtezolizumab + Selicrelumab + BevacizumabAtezolizumab + IdasanutlinAtezolizumab + RegorafenibAtezolizumab + Regorafenib + AB928Atezolizumab + LOAd703Total
American Indian or Alaska Native010000001
Asian7640158031
Native Hawaiian or Other Pacific Islander000000000
Black or African American100001002
White157105376255
More than one race010000001
Unknown or Not Reported101102106
ECOG score
ECOG score(Participants)Regorafenib (Control)Atezolizumab + Imprime PGG + BevacizumabAtezolizumab + IsatuximabAtezolizumab + Selicrelumab + BevacizumabAtezolizumab + IdasanutlinAtezolizumab + RegorafenibAtezolizumab + Regorafenib + AB928Atezolizumab + LOAd703Total
011855177145
1137101388151
Number of Metastatic Sites at Enrollment
Number of Metastatic Sites at Enrollment(Participants)Regorafenib (Control)Atezolizumab + Imprime PGG + BevacizumabAtezolizumab + IsatuximabAtezolizumab + Selicrelumab + BevacizumabAtezolizumab + IdasanutlinAtezolizumab + RegorafenibAtezolizumab + Regorafenib + AB928Atezolizumab + LOAd703Total
1310001106
24533375030
39580026232
>=48443153028
08

Study locations

15 sites
  • City of Hope Comprehensive Cancer Center
    Duarte, California 91010, United States
  • Yale University
    New Haven, Connecticut 06511, United States
  • Dana Farber Cancer Institute
    Boston, Massachusetts 02215, United States
  • Washington University School of Medicine
    Saint Louis, Missouri 63110, United States
  • Columbia University Medical Center
    New York, New York 10032, United States
  • Memorial Sloan-Kettering Cancer Center
    New York, New York 10065, United States
  • Peter MacCallum Cancer Center
    North Melbourne, Victoria 3051, Australia
  • Centre Georges François Leclerc; Pharmacie des Essais Cliniques
    Dijon Cedex, 21079, France
  • Centre Leon Berard
    Lyon, 69008, France
  • Institut Claudius Regaud; Departement Oncologie Medicale
    Toulouse, 31059, France
  • Institut Gustave Roussy
    Villejuif, 94805, France
  • Seoul National University Hospital
    Seoul, 03080, Korea, Republic of
  • Samsung Medical Center
    Seoul, 06351, Korea, Republic of
  • Asan Medical Center.
    Seoul, 5505, Korea, Republic of
  • CHUV; Departement d'Oncologie
    Lausanne, 1011, Switzerland
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Sep 2018 to primary completion in Sep 2022, 47 months.

Results were first posted in Nov 2023, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
May 31, 2018
First posted
Jun 13, 2018
StartActual
Sep 27, 2018
Primary completionActual
Sep 26, 2022
CompletionActual
Sep 26, 2022
Results first posted
Nov 7, 2023
Last update
Nov 7, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 7, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03555149
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Jun 13, 2018
Start date
Sep 27, 2018
Primary completion
Sep 26, 2022
Completion
Sep 26, 2022
Results posted
Nov 7, 2023
Last update
Nov 7, 2023

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Regorafenib · BTH1677 · Bevacizumab · Isatuximab · Selicrelumab · RG7388 · AB928

Start the discussion